402 related articles for article (PubMed ID: 10404594)
21. Structural basis for the inhibitor recognition of human Lyn kinase domain.
Miyano N; Kinoshita T; Nakai R; Kirii Y; Yokota K; Tada T
Bioorg Med Chem Lett; 2009 Dec; 19(23):6557-60. PubMed ID: 19857964
[TBL] [Abstract][Full Text] [Related]
22. Computational analysis of the binding specificity of Gleevec to Abl, c-Kit, Lck, and c-Src tyrosine kinases.
Lin YL; Roux B
J Am Chem Soc; 2013 Oct; 135(39):14741-53. PubMed ID: 24001034
[TBL] [Abstract][Full Text] [Related]
23. The human immunodeficiency virus type 1 Nef protein binds the Src-related tyrosine kinase Lck SH2 domain through a novel phosphotyrosine independent mechanism.
Dutartre H; Harris M; Olive D; Collette Y
Virology; 1998 Aug; 247(2):200-11. PubMed ID: 9705913
[TBL] [Abstract][Full Text] [Related]
24. Determination of the solution structure of the SH3 domain of human p56 Lck tyrosine kinase.
Hiroaki H; Klaus W; Senn H
J Biomol NMR; 1996 Sep; 8(2):105-22. PubMed ID: 8914270
[TBL] [Abstract][Full Text] [Related]
25. Crystal structures of peptide complexes of the amino-terminal SH2 domain of the Syp tyrosine phosphatase.
Lee CH; Kominos D; Jacques S; Margolis B; Schlessinger J; Shoelson SE; Kuriyan J
Structure; 1994 May; 2(5):423-38. PubMed ID: 7521735
[TBL] [Abstract][Full Text] [Related]
26. Demonstration of selective protein kinase C-dependent activation of Src and Lck tyrosine kinases during ischemic preconditioning in conscious rabbits.
Ping P; Zhang J; Zheng YT; Li RC; Dawn B; Tang XL; Takano H; Balafanova Z; Bolli R
Circ Res; 1999 Sep; 85(6):542-50. PubMed ID: 10488057
[TBL] [Abstract][Full Text] [Related]
27. 3D-QSAR studies on c-Src kinase inhibitors and docking analyses of a potent dual kinase inhibitor of c-Src and c-Abl kinases.
Thaimattam R; Daga PR; Banerjee R; Iqbal J
Bioorg Med Chem; 2005 Aug; 13(15):4704-12. PubMed ID: 15914012
[TBL] [Abstract][Full Text] [Related]
28. Differences in binding of PI 3-kinase to the src-homology domains 2 and 3 of p56 lck and p59 fyn tyrosine kinases.
Susa M; Rohner D; Bichsel S
Biochem Biophys Res Commun; 1996 Mar; 220(3):729-34. PubMed ID: 8607833
[TBL] [Abstract][Full Text] [Related]
29. Regulation of the Src family kinase Lck by Hsp90 and ubiquitination.
Giannini A; Bijlmakers MJ
Mol Cell Biol; 2004 Jul; 24(13):5667-76. PubMed ID: 15199125
[TBL] [Abstract][Full Text] [Related]
30. Structure determination of human Lck unique and SH3 domains by nuclear magnetic resonance spectroscopy.
Briese L; Willbold D
BMC Struct Biol; 2003 May; 3():3. PubMed ID: 12734017
[TBL] [Abstract][Full Text] [Related]
31. Phosphoinositide 3-kinase-dependent phosphorylation of the dual adaptor for phosphotyrosine and 3-phosphoinositides by the Src family of tyrosine kinase.
Dowler S; Montalvo L; Cantrell D; Morrice N; Alessi DR
Biochem J; 2000 Jul; 349(Pt 2):605-10. PubMed ID: 10880360
[TBL] [Abstract][Full Text] [Related]
32. The three-dimensional structure of the ZAP-70 kinase domain in complex with staurosporine: implications for the design of selective inhibitors.
Jin L; Pluskey S; Petrella EC; Cantin SM; Gorga JC; Rynkiewicz MJ; Pandey P; Strickler JE; Babine RE; Weaver DT; Seidl KJ
J Biol Chem; 2004 Oct; 279(41):42818-25. PubMed ID: 15292186
[TBL] [Abstract][Full Text] [Related]
33. Discovery and initial SAR of imidazoquinoxalines as inhibitors of the Src-family kinase p56(Lck).
Chen P; Norris D; Iwanowicz EJ; Spergel SH; Lin J; Gu HH; Shen Z; Wityak J; Lin TA; Pang S; De Fex HF; Pitt S; Shen DR; Doweyko AM; Bassolino DA; Roberge JY; Poss MA; Chen BC; Schieven GL; Barrish JC
Bioorg Med Chem Lett; 2002 May; 12(10):1361-4. PubMed ID: 11992777
[TBL] [Abstract][Full Text] [Related]
34. Selective Targeting of SH2 Domain-Phosphotyrosine Interactions of Src Family Tyrosine Kinases with Monobodies.
Kükenshöner T; Schmit NE; Bouda E; Sha F; Pojer F; Koide A; Seeliger M; Koide S; Hantschel O
J Mol Biol; 2017 May; 429(9):1364-1380. PubMed ID: 28347651
[TBL] [Abstract][Full Text] [Related]
35. Damnacanthal is a highly potent, selective inhibitor of p56lck tyrosine kinase activity.
Faltynek CR; Schroeder J; Mauvais P; Miller D; Wang S; Murphy D; Lehr R; Kelley M; Maycock A; Michne W
Biochemistry; 1995 Sep; 34(38):12404-10. PubMed ID: 7547985
[TBL] [Abstract][Full Text] [Related]
36. Regulation of cytotoxic T lymphocyte-associated molecule-4 by Src kinases.
Chuang E; Lee KM; Robbins MD; Duerr JM; Alegre ML; Hambor JE; Neveu MJ; Bluestone JA; Thompson CB
J Immunol; 1999 Feb; 162(3):1270-7. PubMed ID: 9973379
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of p56(lck) tyrosine kinase by isothiazolones.
Trevillyan JM; Chiou XG; Ballaron SJ; Tang QM; Buko A; Sheets MP; Smith ML; Putman CB; Wiedeman P; Tu N; Madar D; Smith HT; Gubbins EJ; Warrior UP; Chen YW; Mollison KW; Faltynek CR; Djurić SW
Arch Biochem Biophys; 1999 Apr; 364(1):19-29. PubMed ID: 10087161
[TBL] [Abstract][Full Text] [Related]
38. Subdomain X of the kinase domain of Lck binds CD45 and facilitates dephosphorylation.
Felberg J; Lefebvre DC; Lam M; Wang Y; Ng DH; Birkenhead D; Cross JL; Johnson P
J Biol Chem; 2004 Jan; 279(5):3455-62. PubMed ID: 14625311
[TBL] [Abstract][Full Text] [Related]
39. Crystal structures of interleukin-2 tyrosine kinase and their implications for the design of selective inhibitors.
Brown K; Long JM; Vial SC; Dedi N; Dunster NJ; Renwick SB; Tanner AJ; Frantz JD; Fleming MA; Cheetham GM
J Biol Chem; 2004 Apr; 279(18):18727-32. PubMed ID: 14766749
[TBL] [Abstract][Full Text] [Related]
40. Neither the LCK nor the FYN kinases are obligatory for IL-2-mediated signal transduction in HTLV-I-infected human T cells.
Mills GB; Arima N; May C; Hill M; Schmandt R; Li J; Miyamoto NG; Greene WC
Int Immunol; 1992 Nov; 4(11):1233-43. PubMed ID: 1472476
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
